Talabostat mesylate

Base Information

• Chemical Name: Talabostat mesylate
• CAS No.: 150080-09-4
• Molecular Formula: C10H23BN2O6S
• Molecular Weight: 310.17
• Hs Code.: 2933990090
• UNII: V8ZG4Y1B51
• ChEMBL ID: CHEMBL3545064
• DSSTox Substance ID: DTXSID70164466
• NCI Thesaurus Code: C80682
• Wikidata: Q27291679
• Mol file: 150080-09-4.mol

Synonyms:L-valinyl-L-boroproline;PT 100;PT-100;PT100 cpd;talabostat;valinyl-boroproline

Chemical Property of Talabostat mesylate

Chemical Property:

• PSA: 149.54000
• LogP: 0.61560
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility.: Soluble in DMSO (up to at least 25 mg/ml)
• Hydrogen Bond Donor Count: 4
• Hydrogen Bond Acceptor Count: 7
• Rotatable Bond Count: 3
• Exact Mass: 310.1369878
• Heavy Atom Count: 20
• Complexity: 328

Purity/Quality:

99% ^*data from raw suppliers

Talabostat Mesylate ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: B(C1CCCN1C(=O)C(C(C)C)N)(O)O.CS(=O)(=O)O
• Isomeric SMILES: B([C@@H]1CCCN1C(=O)[C@H](C(C)C)N)(O)O.CS(=O)(=O)O
• Recent ClinicalTrials: Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
• Recent EU Clinical Trials: A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1 (PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda?) in Patients with mCRPC either Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC) or Adenocarcinoma Phenotype
• Description: Talabostat is a non-selective inhibitor of dipeptidyl peptidases (DPPs), including DPP-4, DPP-7, DPP-8, DPP-9, fibroblast activation protein (FAP), and prolyl endopeptidase (PREP; IC50s = >4, 310, 4, 11, 560, and 390 nM, respectively). It inhibits proliferation of superantigen-stimulated human peripheral blood mononuclear cells (PBMCs; IC50 = ~10 nM). Talabostat (5 μg twice per day) increases expression of a variety of cytokines, including those encoding IL-1β, IL-6, and G-CSF, and chemokines in tumors and tumor-draining lymph nodes in a WEHI-164 fibrosarcoma mouse model. It reduces tumor growth in WEHI-164, MM45T.Sp, and MM52.T fibrosarcoma, EL-4 and A20/2J lymphoma, B16/F10 melanoma, and P815 mastocytoma syngeneic mouse models. Talabostat also increases the efficacy of the antitumor antibodies rituximab and trastuzumab in Namalwa B cell lymphoma and LS180 colon carcinoma mouse xenograft models, respectively.
• Uses: Treatment of cancer; hematopoetic stimulant. Talabostat Mesylate can be used in biological study and pharmacological activity of treatment of cancer using immunomodulation.